



EDAP Received Significant Visibility for Ablatherm-HIFU at American Urological Association Annual Meeting

Four Abstracts Covered Long-Term Positive European Experience Utilizing HIFU Treatment for Localized Prostate Cancer

LYON, France, Jun 8, 2010 (GlobeNewswire via COMTEX News Network) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that it was a major participant at the American Urological Association (AUA) 2010 Annual Meeting, held May 29 -- June 3, 2010 in San Francisco. As part of the scientific program, four abstracts were presented that outlined the long-term positive European experience utilizing EDAP's Ablatherm-HIFU treatment for localized prostate cancer as summarized below.

Marc Oczachowski, EDAP's Chief Executive Officer, commented, "We were pleased with the strong reception that our technology and products received at AUA 2010. This prestigious meeting attracts a broad spectrum of urologists from both the U.S. and around the globe. The four abstracts that were presented represented the largest studies ever conducted among HIFU devices. We are proud of the positive reception that these studies received and expect that awareness will continue to grow globally. These results confirm that this lifestyle preserving treatment for localized prostate cancer is on par with other more invasive treatment options such as surgery."

- "Outcomes of HIFU for Prostate Cancer in 880 Consecutive Patients," presented by Dr. Crouzet, Lyon, France. This is the largest multi-center study ever presented of patients, who have undergone HIFU as a primary therapy for prostate cancer, and included patients treated successfully for more than 10 years ago. This study was facilitated by the @-Registry (also called the "Ablatherm Treatment" Registry), the largest database of Ablatherm-HIFU patients ever compiled. The results showed success of HIFU on par with the traditional therapies of surgery and radiation therapy.
- "HIFU Following Failed Radiation Therapy: Biochemical Survival of Ablatherm Registry," presented by Dr. John Ward, MD Anderson, Houston Texas. This is the largest patient series ever presented of patients who have undergone HIFU as a curative treatment after failed radiation therapy. Collected with the @-Registry, data from 434 men demonstrated no biochemical evidence of prostate cancer in over half of men four years after treatment. The paper concluded that the results were encouraging and showed the ability to return men to disease free status with HIFU after failed radiation therapy.
- "Correlation of Different PSA-Nadir Cut Offs and Biochemical Failure After High Intensity Focused Ultrasound (HIFU) of Prostate Cancer Based on the Stuttgart Failure Criteria," presented by Dr. Roman Ganzer, Regensburg University, Regensburg, Germany. This study confirmed earlier observations that patients get a very early indication of the successfulness of their treatment. The study stated this is important because if a treatment is not successful, early confirmation of this allows for early action to retreat. This is not possible with radiation therapy, which requires 18-24 months post treatment to determine success.
- "Hormone Resistant Prostate Cancer Treated by Robotic High Intensity Ultrasound," presented by Christian Chaussy, Harlaching Hospital, Munich, Germany. Hormone therapy is used to treat metastatic prostate cancer. When the disease becomes resistant to hormones, therapy becomes palliative and life expectancy rapidly shortens. In this study, 55 men with hormone resistant prostate cancer were treated with HIFU and followed up to 9.5 years. The study concluded that adjuvant HIFU

achieved a longer survival with good quality of life.

Based on his strong experience at the largest European Ablatherm-HIFU center, Harlaching Hospital in Munich, Germany, Pr. Christian Chaussy presented an update on HIFU technology for the treatment of localized prostate cancer during a special program dedicated to the Engineering and Urology Society, which promotes the development and application of new technology in urology through the collaborative efforts of engineers, physicists, and urologists. The presentation focused on the engineering community, which is involved in the endorsement and selection of innovative technologies such as HIFU.

Dr. John Rewcastle, EDAP TMS Medical Director, concluded, "These studies, which together report the outcomes of over 1,350 men who have undergone HIFU, underscore the versatility, dependability and success of HIFU as a prostate cancer treatment. Specifically, the large primary and salvage series substantiate earlier observations of HIFU's efficacy but now on a much larger scale. The hormone resistant treatment is novel and may prove to be a valuable treatment for a population of men with limited options."

About EDAP TMS SA

EDAP TMS SA develops and markets Ablatherm, the most advanced and clinically proven choice for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Approved in Europe as a treatment for prostate cancer, Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently undergoing evaluation in a multicenter U.S. Phase II/III clinical trial under an Investigational Device Exemption granted by the FDA, the ENLIGHT U.S. clinical study. The Company also is developing this technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit <http://www.edap-tms.com>, <http://www.hifu-planet.com>.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: EDAP TMS SA

CONTACT: EDAP TMS SA
Investor Relations / Legal Affairs
Blandine Confort
+33 4 72 15 31 72
bconfort@edap-tms.com
The Ruth Group
Investors:
Stephanie Carrington
646-536-7017
scarrington@theruthgroup.com

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX